2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1784

Treatment with Belimumab in SLE Does Not Impair Antibody Response to 13-Valent Pneumococcal Conjugate Vaccine
Abstract Number: 1785

Clinical Characteristics and Relative Factors of Infections in Southern Chinese Patients with Systemic Lupus Erythematosus
Abstract Number: 1786

Improvements in Health-Related Quality of Life and Fatigue Following Administration of an IL-6 Monoclonal Antibody (PF-04236921) in an Enriched Population of Subjects with Active SLE
Abstract Number: 1787

Innate Immunity, Arterial Inflammation and Vascular Stiffness in Patients with Systemic Lupus Erythematosus
Abstract Number: 1788

Lipoprotein Subfractions and Cardiovascular Disease in Systemic Lupus Erythematosus
Abstract Number: 1789

Infections Observed in Rituximab Treated Patients with Refractory Systemic Lupus Erythematosus (SLE): Results from a National Multicentre Register
Abstract Number: 1790

Mycophenolate Mofetil Suppresses Humoral Response to Pneumococcal Vaccine in Patients with Systemic Lupus Erythematosus and Other Autoimmune Diseases
Abstract Number: 1791

Does Renin-Angiotensin System Blockade Protect Lupus Nephritis Patients from Atherosclerotic Cardiovascular Events? a Case-Control Study
Abstract Number: 1792

Optimal Monitoring for Coronary Heart Disease Risk in Systemic Lupus Erythematosus Patients: a Systematic Review
Abstract Number: 1793

Is There a Relationship Between Antimalarial Treatment and Elevated Muscle Enzymes in Systemic Lupus Erythematosus
Abstract Number: 1794

Unexplained Decline in Rates of Cardiovascular Events in a Large Cohort of SLE Patients
Abstract Number: 1795

Long-Term Safety and Efficacy of Tacrolimus for Lupus Nephritis Patients in Real World Setting -Results from 5 Year Interim Analysis of Post Marketing Surveillance of 1376 Patients in Japan-
Abstract Number: 1796

Progression of Atherosclerosis Might be Prevented By Decrease of Serum Resistin Level after Glucocorticoid Therapy in Patients with Systemic Autoimmune Disease
Abstract Number: 1797

Insulin Resistance Is Not Associated with Increased Risk of Subclinical Atheromatosis in Patients with Systemic Lupus Erythematosus from Northern Spain
Abstract Number: 1798

Progression of Noncalcified and Calcified Coronary Plaque (by CT Angiography) in SLE

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].